DNAprint Genomics (DNAG)

[ann441j]

Info on NNBP:

Nanobac Pharmaceuticals wants to pick on something much smaller than its own size. The company is researching nanobacteria, tiny organisms that are 100 times smaller than bacteria, yet apparently cause the body to develop calcium buildup in inconvenient places such as artery walls and kidneys. Such nanobacteria are also called calcifying nano-particles (CNPs) due to their mineralizing properties. Nanobac is researching combinations of already-approved drugs to halt the calcification process. The company also develops and manufactures diagnostic test kits to identify CNPs in the blood. CEO John Stanton controls more than 40% of the company.

Sample Overview
Key Numbers
Company Type Public (OTC: NNBP)
Fiscal Year-End December
2006 Sales (mil.) $0.2
1-Year Sales Growth (65.2%)
2006 Net Income (mil.) ($5.0)

More Financials
Key People
Chairman, CEO, and CFO John Stanton
Co-chairman, Chief Medical Officer, and Head of Operations Benedict Maniscalco

Ann